Immunohistochemical Biomarkers in Ductal Carcinoma &amp;lt;i&amp;gt;In Situ&amp;lt;/i&amp;gt;

I Petrone,E Abdelhay,F Resende Rodrigues,P Valverde Fernandes

doi:10.4236/ojpathology.2020.104013

Abstract

Introduction: Breast ductal carcinoma In Situ (DCIS) can be defined as a malignant epithelial proliferation with growth limited by the basal membrane of the ductal epithelium, with no evidence of stromal invasion. There has been a trend of trying to subcategorize DCIS based on cell proliferation assays (Ki67) and the expression of hormone receptors and the human epidermal growth receptor (HER-2) as detected by immunohistochemistry, similar to invasive breast carcinomas (IBC). The aims were to evaluate the expression of breast cancer marker proteins in DCIS by immunohistochemistry to better categorize it. Methods: 46 biopsies from women with DCIS and IBC Luminal A-like were evaluated by immunohistochemistry staining of proteins already known to be biomarkers in IBC. For controls, normal breast tissue from mammoplasty (n = 3) was used. Results: Our results showed an increase of estrogen receptor (ER) and progesterone receptor (PR) expression relative to that in normal tissue samples (p

Highlights

Breast ductal carcinoma in situ (DCIS) can be defined as a malignant epithelial proliferation with growth limited by the basal membrane of the ductal epithelium, with no evidence of stromal invasion
Genomic studies have provided new information about breast cancer heterogeneity, which has allowed its classification into four intrinsic subtypes based on hormone receptor expression: Luminal, which expresses the estrogen receptor (ER) and/or the progesterone receptor (PR); Luminal-HER-2, which is characterized by expression of the estrogen and/or progesterone receptor and the human epidermal growth factor receptor 2; HER-2, which is characterized by HER-2 overexpression but not expression of the two hormone receptors; and triple negative, which does not express any of these three receptors [3] [4]
A total of 46 biopsies of female patients without any prior chemotherapy treatment who were diagnosed with DCIS or invasive breast carcinomas (IBC) were evaluated in the present study

Summary

Introduction

Breast ductal carcinoma in situ (DCIS) can be defined as a malignant epithelial proliferation with growth limited by the basal membrane of the ductal epithelium, with no evidence of stromal invasion. Genomic studies have provided new information about breast cancer heterogeneity, which has allowed its classification into four intrinsic subtypes based on hormone receptor expression: Luminal, which expresses the estrogen receptor (ER) and/or the progesterone receptor (PR); Luminal-HER-2, which is characterized by expression of the estrogen and/or progesterone receptor and the human epidermal growth factor receptor 2; HER-2, which is characterized by HER-2 overexpression but not expression of the two hormone receptors; and triple negative, which does not express any of these three receptors [3] [4] This classification has been applied to invasive breast carcinoma (IBC) and is important in making therapeutic choices for patients. Weaker risk factors, such as a high body mass index, have been inconsistently associated with the risk of DCIS, and genetic risk factors have been described as being similar to those for IBC: BRCA1 and BRCA2 mutation carriers develop DCIS more frequently and at an earlier age than the general population [12] [13]

Methods

Results

Discussion

Conclusion